SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Chronic kidney disease (CKD) is a global health problem with rising incidence and
prevalence. Among several pathogenetic mechanisms responsible for disease progression …

Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …

Loss of normal kidney function affects more than 10% of the population and contributes to
morbidity and mortality. Kidney diseases are currently treated with immunosuppressive …

Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes,
and elevated GFR is a risk factor for the development of diabetic kidney disease …

The increasing global prevalence of type 2 diabetes mellitus (T2DM) and chronic kidney
disease (CKD) has prompted research efforts to tackle the growing epidemic of diabetic …

Sodium/glucose cotransporter 2 (SGLT2) inhibitors exert important renoprotective effects in
the diabetic kidney, which cannot be readily explained by their actions to lower blood …

The molecular mechanisms of sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i)
remain incompletely understood. Single-cell RNA sequencing and morphometric data were …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

RY rheostat, whereas AMPK discerns the balance between ATP and AMP in the cytosol.
Importantly, SIRT1 and AMPK are activated not only by fasting but also by a broad range of …